OS Therapies Incorporated

AMEX:OSTX

Biotechnology

Healthcare
$1.15 +5.81%

+$0.10 today

Market cap
$53.83M
Beta
-0.95
P/E (TTM)
-2.0
EPS (TTM)
-$0.91
52W Low $1.15High $2.57

Volume 0.50M

Average 0.71M

OSTX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

OS Therapies IncorporatedAMEX: OSTX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 38.67M shares rose 82.0% year over year, ahead of the -31.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 32.2% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +82.0% holds above the trailing-twelve-month pace of -31.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
38.67M+32.2% QoQ
Last fiscal yearDec 2025
29.25M+40.2% YoY
LTMMar 2026
31.25M-31.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+82.0%——
1 year+40.2%——
3-year CAGR+8.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
29.25M USD
Year-over-year change
+40.2%
4-year CAGR
+6.1%

Weighted Avg Shares (Diluted) vs competitors

How OSTX compares with its peers on the latest reported figures

  • OSTX's LTM Mar 2026 weighted avg shares (diluted) of 31.25M shares is the 4th highest of the 9 companies compared; the peer median is 27.2M shares.
  • Its year-over-year change of -31.1% is the 7th highest of 8, against a peer median of +14.4%.
  • Over three fiscal years its annual growth of +8.2% compares with a peer median of +8.0%.
OSTX Competitors Peer median
Weighted Avg Shares (Diluted) for OSTX and competitors
Company Period LTM YoY 3-year CAGR
EQEquillium, Inc.LTM Mar 202664.9M +81.6%+39.7%
HOWLWerewolf Therapeutics, Inc.LTM Jun 202647.65M +7.1%+17.5%
ADAGAdagene Inc.LTM Jun 202435.23M —+2.9%
OSTXOS Therapies IncorporatedLTM Mar 202631.25M -31.1%+8.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 202628.35M +14.4%+33.9%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
COEPCoeptis Therapeutics, Inc.LTM Mar 20264.68M -77.3%-33.3%
INKTMiNK Therapeutics, Inc.LTM Mar 20264.37M +13.5%+8.2%
SPRBSpruce Biosciences, Inc.LTM Mar 2026827.01K +51.8%+7.8%
Peer median (excluding OSTX) 27.2M+14.4%+8.0%

Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.16M8054.22K2.78K363.09K
Gross Profit(1.16M)(805)(4.22K)(2.78K)(363.09K)
Gross Margin—————
Research & Development2.17M3.29M3.22M2.84M16.36B
Selling, General & Admin1.5M1.15M1.12M3.97M12.34B
Operating Expenses3.68M4.45M4.34M6.81M28.34M
Depreciation & Amortization8058054.22K2.78K363.09K
EBITDA(4.84M)(4.45M)(4.34M)(6.83M)(28.39M)
EBITDA Margin—————
Operating Income(4.84M)(4.45M)(4.34M)(6.81M)(28.71M)
Operating Margin—————
Interest Income0000249
Interest Expense2.58M1.81M3.45M2.05M0
Other Income / Expenses(2.58M)(1.81M)(3.45M)(2.07M)(48.14K)
Income Before Tax(7.42M)(6.25M)(7.79M)(8.88M)(28.75M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(7.42M)(6.25M)(7.79M)(8.88M)(28.75M)
Net Margin—————
EPS (Basic)(0.33)(0.28)(0.39)(0.52)(0.98)
EPS (Diluted)(0.33)(0.28)(0.39)(0.52)(0.98)
Weighted Avg Shares23.1M23.1M20.05M20.87M29.25M
Weighted Avg Shares (Diluted)23.1M23.1M20.05M20.87M29.25M

OS Therapies Incorporated

AMEX:OSTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.